Table 3 Baseline characteristics in all subjects with or without MACEs
From: Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus
| Â | Total | MACEs group | Non- MACEs group | p value |
|---|---|---|---|---|
Clinical characteristics | Â | Â | Â | Â |
N (%) | 2984 | 373 (12.50%) | 2611 (87.50%) | – |
Age (years) | 57.48 ± 9.93 | 58.42 ± 11.37 | 57.34 ± 9.69 | 0.265 |
Male (%) | 1732 (58.04%) | 225 (60.32%) | 1507 (57.72%) | 0.340 |
BMI (kg/m2) | 25.23 ± 3.07 | 24.89 ± 2.62 | 25.27 ± 3.14 | 0.329 |
Hypertension (%) | 2084 (69.53%) | 276 (73.99%) | 1808 (69.25%) | 0.062 |
Smoking (%) | 838 (28.08%) | 108 (28.95%) | 730 (27.96%) | 0.689 |
Alcohol consumption (%) | 887 (29.73%) | 110 (29.49%) | 777 (29.75%) | 0.916 |
Family history of CHD (%) | 851 (28.52%) | 131 (35.12%) | 720 (27.58%) | 0.003 |
Family history of MD (%) | 1135 (38.04%) | 146 (39.14%) | 989 (37.88%) | 0.638 |
Laboratory variables | Â | Â | Â | Â |
FPG (mmol/L) | 7.69 ± 1.16 | 7.73 ± 1.13 | 7.68 ± 1.15 | 0.679 |
HbA1c (%) | 7.52 ± 1.10 | 7.58 ± 1.13 | 7.51 ± 1.09 | 0.492 |
ApoB (mg/dL) | 85.10 (26.85) | 90.00 (33.90) | 84.52 (25.79) | 0.008 |
ApoA1 (mg/dL) | 144.1 (37.55) | 144.35 (34.57) | 144.10 (37.70) | 0.874 |
Total cholesterol (mmol/L) | 4.44 (1.34) | 4.59 (1.30) | 4.43 (1.33) | 0.013 |
Triglycerides (mmol/L) | 1.32 (0.88) | 1.37 (0.91) | 1.31 (0.87) | 0.411 |
HDL-C (mmol/L) | 1.14 (0.35) | 1.09 (0.37) | 1.14 (0.35) | 0.257 |
LDL-C (mmol/L) | 2.73 (0.94) | 2.73 (1.16) | 2.73 (0.92) | 0.161 |
Lp(a) (nmol/L) | 39.24 (39.77) | 39.51 (41.25) | 39.31 (40.03) | 0.527 |
hs-CRP (mg/L) | 1.38 (1.69) | 1.32 (1.73) | 1.39 (1.66) | 0.312 |
HCY (umol/L) | 11.65 (7.69) | 11.79 (6.88) | 11.62 (7.86) | 0.941 |
sdLDL-C (mmol/L) | 0.74 (0.37) | 0.80 (0.39) | 0.73 (0.37) | 0.048 |
PCSK9 (ng/mL) | 521.98 (209.78) | 644.66 (310.41) | 511.01 (169.12) | < 0.001 |